We are studying a new infusion treatment called CART84 for patients with relapsed or refractory acute myeloid leukemia and acute lymphoblastic T leukemia. The goal is to evaluate its safety and effectiveness in helping patients achieve remission.
Health conditions and diseases that the clinical trial is designed to study and treat.
Relapsed/Refractory Acute Lymphoblastic T Leukemia (T-ALL) is a type of blood cancer that affects the bone marrow and blood, characterized by the overproduction of immature T-cells. It can return after treatment or not respond to initial therapies.
Relapsed/Refractory Acute Myeloid Leukemia (AML) is a type of cancer that starts in the blood-forming cells of the bone marrow and leads to the rapid growth of abnormal white blood cells. It can return after treatment or not respond to initial therapies.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.